Biotranex is a science-driven Contract Research Organization (CRO) that provides clients with a full range of ADMET and pharmacokinetic laboratory and consulting services to facilitate drug discovery and development. Services that Biotranex offers include metabolite profiling and structural elucidation; drug-drug interaction studies; CYP induction and inhibition; CYP and UGT phenotyping; transporter inhibition and phenotyping; metabolite biosynthesis; subcellular, hepatocyte, and animal studies; biotransformation; and pharmacokinetic studies. The Biotranex team of scientists has extensive collective experience in the pharmaceutical industry and proven drug discovery and development successes, as well as extensive experience with IND and NDA regulatory filings.
MDR3cyte™ Inhibition Assay
MDR3cyte™ is a patent-pending assay that is the only physiologically relevant assay available to assess test agent inhibition of human multidrug resistance protein 3 (MDR3). MDR3cyte™ is a hepatocyte-based platform that measures test agent inhibition of MDR3, provides cross-species studies, and offers the ability to investigate the effect of in situ drug metabolism on inhibition; the assay is run without radioactive reagents.
MDR3cyte™ employs a 96-well plate format with liquid chromatography-mass spectrometry quantification. The assay is accurate, reproducible, sensitive, and possesses a wide dynamic range. MDR3cyte™ was developed to be cost competitive and high-throughput.
MDR3cyte™ shows excellent correlation with drugs that cause human drug-induced liver injury (DILI) and MDR3 inhibition. MDR3cyte™ is your assay to test MDR3 inhibition and minimize the risk of unexpected DILI.
BSEPcyte® Hepatocyte-Based BSEP Inhibition Assay
BSEPcyte™ is a patented assay (United States patent number 9,772,325) that offers significant advantages over bile salt export pump (BSEP) assays that use membrane vesicle preparations. BSEPcyte™ is a physiologically relevant hepatocyte-based platform that measures test agent inhibition of BSEP or Bsep, provides cross-species comparisons, and offers the ability to investigate the effect of in situ drug metabolism on inhibition; the assay is run without radioactive reagents.
BSEPcyte™ employs a 96-well plate format with liquid chromatography-mass spectrometry quantification. The assay is accurate, reproducible, sensitive, and possesses a wide dynamic range. BSEPcyte™ was developed to be cost competitive and high-throughput.
BSEPcyte™ shows excellent correlation with drugs that cause human drug-induced liver injury (DILI) and BSEP inhibition. BSEPcyte™ is your assay to test BSEP inhibition and minimize the risk of unexpected DILI.
Biotranex provides laboratory services for pharmacokinetics/metabolism/chemical toxicology studies including:
Biotranex provides a full range of services to study drug absorption and transporter properties to meet the FDA and EMA Guidance:
Biotranex offers services to scale up metabolite production using bioreactors and chemical synthesis:
Biotranex offers integrated drug discovery services including:
Biotranex provides consulting services for IND and NDA filings:
Clinical Research Services
Pharmacology Services
"It is a great experience working with Biotranex. They provide great and speedy services!"
Biotranex LLC has not received any endorsements.